Therapeutic Advances and New Directions for Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis, primarily treated with chemotherapy.
• Germline mutations in DNA-damage repair genes (e.g., BRCA1/2) occur in up to 20% of TNBC patients, indicating potential targeted therapy responses.
• Tumor molecular subtypes and genetic heterogeneity explain TNBC's diverse behavior and treatment responses.

Purpose of the Study:

• To review current standard and experimental treatment options for triple-negative breast cancer.
• To highlight how understanding TNBC's molecular and genetic heterogeneity guides therapeutic strategies.
• To discuss novel trial designs and endpoints for expediting therapy development in high-risk breast cancer.

Main Methods:

• Genotyping studies to identify distinct molecular subtypes of TNBC.
• Analysis of therapeutic vulnerabilities across different biological processes (proliferation, DNA repair, etc.).
• Review of current clinical trial designs and surrogate endpoints for early-stage breast cancer.

Main Results:

• Molecular subtyping has decoded TNBC's heterogeneity, revealing subtype-specific therapeutic targets.
• Identification of 'BRCA-like' tumor biology in TNBC subtypes suggests targeted therapy potential beyond BRCA mutations.
• Novel trial designs and endpoints are being implemented to accelerate therapy development.

Conclusions:

• Targeting DNA-damage repair pathways, including BRCA and BRCA-like alterations, is crucial for TNBC treatment selection.
• Understanding TNBC's molecular landscape enables the identification of specific vulnerabilities for tailored therapies.
• Advancements in trial design and endpoints are vital for developing new treatments for high-risk breast cancer.